165 related articles for article (PubMed ID: 28065383)
1. Molecular alterations contributing to pancreatic cancer chemoresistance.
Rajabpour A; Rajaei F; Teimoori-Toolabi L
Pancreatology; 2017; 17(2):310-320. PubMed ID: 28065383
[TBL] [Abstract][Full Text] [Related]
2. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance.
Kaoutari AE; Fraunhoffer NA; Hoare O; Teyssedou C; Soubeyran P; Gayet O; Roques J; Lomberk G; Urrutia R; Dusetti N; Iovanna J
EBioMedicine; 2021 Apr; 66():103332. PubMed ID: 33862584
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
[TBL] [Abstract][Full Text] [Related]
6. Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives.
Rahnama N; Jahangir M; Alesaeid S; Kahrizi MS; Adili A; Mohammed RN; Aslaminabad R; Akbari M; Özgönül AM
Pathol Res Pract; 2022 Aug; 236():153982. PubMed ID: 35779293
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-gene signaling pathways in pancreatic cancer.
Drakaki A; Iliopoulos D
Biomed J; 2013; 36(5):200-8. PubMed ID: 24225187
[TBL] [Abstract][Full Text] [Related]
8. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Nambaru PK; Hübner T; Köck K; Mews S; Grube M; Payen L; Guitton J; Sendler M; Jedlitschky G; Rimmbach C; Rosskopf D; Kowalczyk DW; Kroemer HK; Weiss FU; Mayerle J; Lerch MM; Ritter CA
Drug Metab Dispos; 2011 Jan; 39(1):132-9. PubMed ID: 20930123
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for advanced pancreatic cancer: a review.
Warsame R; Grothey A
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1327-36. PubMed ID: 23176620
[TBL] [Abstract][Full Text] [Related]
10. Recent studies of 5-fluorouracil resistance in pancreatic cancer.
Wang WB; Yang Y; Zhao YP; Zhang TP; Liao Q; Shu H
World J Gastroenterol; 2014 Nov; 20(42):15682-90. PubMed ID: 25400452
[TBL] [Abstract][Full Text] [Related]
11. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer.
Noma B; Sasaki T; Fujimoto Y; Serikawa M; Kobayashi K; Inoue M; Itsuki H; Kamigaki M; Minami T; Chayama K
Int J Oncol; 2008 Dec; 33(6):1187-94. PubMed ID: 19020751
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells.
Huang B; Wang J; Chen Q; Qu C; Zhang J; Chen E; Zhang Y; Wang Y; Ni L; Liang T
Am J Transl Res; 2019; 11(1):473-485. PubMed ID: 30788003
[TBL] [Abstract][Full Text] [Related]
13. Microarray analysis of gene expression profile of multidrug resistance in pancreatic cancer.
Zhao YP; Chen G; Feng B; Zhang TP; Ma EL; Wu YD
Chin Med J (Engl); 2007 Oct; 120(20):1743-52. PubMed ID: 18028764
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in pancreatic cancer: Impact of altered energy metabolism.
Grasso C; Jansen G; Giovannetti E
Crit Rev Oncol Hematol; 2017 Jun; 114():139-152. PubMed ID: 28477742
[TBL] [Abstract][Full Text] [Related]
15. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.
Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ
Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074
[TBL] [Abstract][Full Text] [Related]
16. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.
El Maalouf G; Le Tourneau C; Batty GN; Faivre S; Raymond E
Cancer Treat Rev; 2009 Apr; 35(2):167-74. PubMed ID: 19027240
[TBL] [Abstract][Full Text] [Related]
17. The promise of epigenomic therapeutics in pancreatic cancer.
Lomberk GA; Iovanna J; Urrutia R
Epigenomics; 2016 Jun; 8(6):831-42. PubMed ID: 27337224
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
Dhayat S; Mardin WA; Mees ST; Haier J
Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
[TBL] [Abstract][Full Text] [Related]
20. Noncoding RNAs in drug-resistant pancreatic cancer: A review.
Lin Z; Lu S; Xie X; Yi X; Huang H
Biomed Pharmacother; 2020 Nov; 131():110768. PubMed ID: 33152930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
